| Literature DB >> 35750877 |
Ming Ji1, Wenliang Gong1, Siman Wang1, Dianjun Zhang1, Binjie Chen1, Xinyu Li1, Xiafang Wu1, Lulu Cui1, Yuliang Feng1, Alexei Verkhratsky2,3,4,5, Baoman Li6.
Abstract
Accumulating evidence suggests that the activation of nucleotide-binding domain and leucine-rich repeat protein-3 (NLRP3) inflammasome contributes to the pathophysiology of post-traumatic stress disorder (PTSD). Astrocytes, the homeostatic cells of the central nervous system are intimately involved into pathophysiology of various mental disorders including PTSD. We demonstrated previously that leptin exerts neuroprotection and ameliorates chronic sleep deprivation-induced depressive-like behaviours. Here, we extended the study of therapeutic effects of leptin to PTSD model mice. We discovered that PTSD is associated with significant activation of NLRP3 inflammasome in astrocytes sorted from GFAP-GFP transgenic mice, while administration of leptin markedly suppressed the activation of astrocytic NLRP3 inflammasome. Leptin effectively improved PTSD-associated behavioural alterations including fear memory, cognitive impairments, and depressive-like behaviours. Therapeutic effects of leptin were mediated by the signal transducer and activator of transcription 3 (STAT3) in astrocytes. In addition, the PTSD-related activation of NLRP3 inflammasome impairs astrocytic mitochondria suppressing ATP synthesis and leading to an increased ROS production. Leptin reversed mitochondrial inhibition by stimulating STAT3 in astrocytes. We propose leptin as a novel candidate for the pharmacological treatment of PTSD.Entities:
Keywords: Astrocytes; Leptin; NLRP3 inflammasome; Post-traumatic stress disorder; STAT3
Year: 2022 PMID: 35750877 DOI: 10.1007/s11064-022-03655-4
Source DB: PubMed Journal: Neurochem Res ISSN: 0364-3190 Impact factor: 3.996